Option Care Health, Inc. (OPCH)
NEUTRALFundamental
72
Price
$23.36
Market Cap
$3.58B
Part 1 · What the company is worth
Overview
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$5.67B
Trailing 12 months (through 3/31/2026)
Net Income
$206M
Trailing 12 months (through 3/31/2026)
Free Cash Flow
$217M
Total Equity
$1.33B
Total Liabilities
$2.13B
Current Ratio
1.64
Interest Coverage
6.06
Debt/EBITDA
3.13
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$30.30
Current Price
$23.36
Margin of Safety
+22.9%
Fair Value Range
$19.70 - $40.91
Estimation Methods
Valuation Metrics
P/E Ratio
18.49
ROE
15.7%
P/B Ratio
2.75
P/FCF
17.49
Gross Margin
19.2%
ROIC
9.9%
Profitability Radar
Value Creation (Economic Moat)
ROIC
9.9%
WACC
6.8%
ROIC − WACC
+3.1 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (20)
- EPS shows upward trend
- EPS CAGR 15.84%
- Price CAGR 19.01%
- ROIC 9.9%
- P/FCF 17.49
- P/B Ratio 2.75
- Debt/Equity ratio
- Operating Margin 5.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.8%
- Revenue Growth 5Y 13.3%
- Analyst Consensus 68% Buy
- Earnings Quality (OCF/NI) 1.23
- Share Dilution -5.1%
- Piotroski F-Score 5/9
Failed (6)
- Gross Margin 19.2%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 2.4%
- Net Margin Trend 3.6% vs 4.1%
Unavailable (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. John Charles Rademacher | CEO, President & Director | 58 |
| Mr. Luke Whitworth | Chief Operating Officer | 44 |
| Mr. Collin G. Smyser | General Counsel & Corporate Secretary | 46 |
| Ms. Nicole Maggio | Senior VP, Controller & Principal Accounting Officer | 42 |
| Mr. Brett Michalak | Chief Technology Officer | - |
| Ms. Alyssa Moy | Chief Information Officer | - |
| Ms. Stacey Mahone | Senior VP & Chief Compliance Officer | - |
| Mr. Jorge Ramirez | Senior VP of Strategy and Corporate Development | - |
| Mr. Michael Bavaro | Chief Human Resources & Chief Diversity Officer | 47 |
| Ms. Julie Koenig | Senior Vice President of Operations | - |
Audit Risk
1
Board Risk
2
Compensation Risk
4
Shareholder Rights Risk
5
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for OPCH, sourced from Markets Gazette.
- 2/24/2026NEUTRALOption Care (OPCH) Earnings Call Transcript
Investors in Option Care Health (OPCH) are awaiting the release of the earnings call transcript, scheduled for February 24, 2026. While the specific content is not yet available, this event is crucial for understanding the company's financial performance and future outlook. Earnings calls provide detailed insights into revenues, profits, margins, and guidance, which are fundamental elements for assessing a company's operational and strategic health. The analysis of this data will enable analysts and shareholders to make informed judgments about the stock's short- to medium-term trajectory. The current lack of content implies a waiting period for the market, which will react once the information is made public.
via Markets Gazette